Investment Overview - The company announced an investment of 150 million RMB in Nuance Biotech (referred to as "优锐开曼") through its wholly-owned subsidiary, 康辰药业（香港）有限公司 [1][2] - The investment consists of 50 million RMB in rental contributions and 100 million RMB in cash [1][2] - Following this investment, the total investment in 优锐开曼 by the company will amount to 312.03 million RMB, with a shareholding exceeding 5% [2] Company Profile - 优锐开曼 is a biopharmaceutical company based in the Cayman Islands, focusing on innovative drug development, particularly in respiratory diseases and iron deficiency anemia [2][3] - The company is currently developing Ensifentrine, a dual-target inhaled phosphodiesterase inhibitor for the treatment of chronic obstructive pulmonary disease (COPD), which has received approval in the US and is in the process of applying for approval in China [2][3] Financial Data - As of March 31, 2025, 优锐开曼 reported total assets of approximately 1.07 billion RMB and total liabilities of approximately 3.09 billion RMB [4] - The company has not been profitable in the last five years, with a net loss of approximately 41.61 million RMB for the fiscal year 2024 [4] Transaction Details - The investment will be used for business expansion, capital expenditures, and operational funding to support the drug application process [1][5] - The transaction is structured as a Series E Preferred Share Purchase Agreement, with 康辰香港 acquiring 38,439,537 shares [1][4] Strategic Implications - The investment is expected to enhance the strategic partnership between the company and 优锐开曼, leveraging each other's strengths in the pharmaceutical market [8] - The company aims to utilize 优锐开曼's resources and expertise to expand its international collaboration in innovative and original drug commercialization [8]